Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative void-ing, sexual dysfunction and pelvic pain. Chronic prostatitis/chronic pelvic pain syn-drome weakens the quality of life and poses adverse psychological effects on the pa-tients. A wide range of treatments, including botulinum neurotoxins, anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phos-phodiesterase type 4 inhibitor, phosphodiesterase type 5 inhibitor, monoclonal anti-body, anticholinergics, gabapentin, pregabalin are used clinically. These therapies em-phasise on easing the symptoms in specific areas without curing the fundamental cause where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective to treat this condition. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Nasrin Aktar, Ahmed Moudud, Tingting Chen, Xiaoqing Gao, Hanhui Min, Meng Tang, Xiaohui Zhou. Recent advances in pharmacological interventions of chronic prostatitis/chronic pelvic pain syndrome. Current pharmaceutical design. 2021 Mar 22


PMID: 33749554

View Full Text